Trials / Completed
CompletedNCT01318941
Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
LUMINOUS: Study to Observe the Effectiveness and Safety of Ranibizumab Through Individualized Patient Treatment and Associated Outcomes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30,490 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in the local product label.
Conditions
- Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Wet Age Related Macular Degeneration
- Diabetic Macular Edema
- Retinal Vein Occlusion
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | |
| OTHER | Ranibizumab |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2011-03-21
- Last updated
- 2016-05-23
Locations
463 sites across 43 countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Costa Rica, Czechia, Dominican Republic, Ecuador, Egypt, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Panama, Peru, Poland, Portugal, Russia, Saudi Arabia, Singapore, Slovakia, Slovenia, South Korea, Spain, Turkey (Türkiye), Ukraine, United Kingdom, Venezuela
Source: ClinicalTrials.gov record NCT01318941. Inclusion in this directory is not an endorsement.